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Shiga Toxin–
producing 
Escherichia coli, 
Idaho
To the Editor: Data collected 
from expanded surveillance study 
suggest that more than half of Idaho 
Shiga toxin–producing Escherichia 
coli  (STEC) illnesses are caused by 
non-O157 serotypes. Using data from 
a regional medical center whose stool 
culture protocol included Shiga toxin 
testing, we predicted Idaho’s STEC 
incidence to be signiﬁ  cantly higher if 
non-O157 STEC E. coli were routine-
ly detected by immunoassay. Recent 
ﬁ   ndings suggest that the prediction 
was accurate in an expanded surveil-
lance area.
Several studies have shown an 
increased incidence of non-O157 
STEC infections in the United States. 
For example, a community hospital 
in Virginia detected non-O157 sero-
types in 31% of patients with STEC 
from 1995–2002 (1). A 1998 Nebraska 
study that analyzed 30,000 diarrheal 
stool samples found that non-O157 
and O157:H7 STEC were equally 
prevalent (2). Additionally, ﬁ  ndings 
from a Connecticut study of labora-
tory-conﬁ  rmed cases (3), STEC sur-
veillance results from Montana (4), 
and a recent study from Michigan 
(5) indicate that non-O157 serotypes 
comprise a substantial percentage of 
STEC cases. 
In other countries, nonculture-
based methods are routinely used for 
STEC detection (6). However, E. coli 
O157:H7 culture methods remain the 
focus in the United Kingdom, Canada, 
and the United States (6). Reliance on 
culture methods can result in mislead-
ing interpretations of STEC preva-
lence. For example, 93% of STEC 
infections in Canada are reported to 
be E. coli O157:H7, yet a Manitoba 
1992 study showed that when toxin 
assays were used, 35% of the recov-
ered STEC isolates were non-O157 
serotypes (6).
Analysis of reported non-O157 
STEC cases in Idaho showed a simi-
lar trend. From 2002–2004, 66% of 
Idaho’s non-O157 cases originated 
in Health District 7, where >70% of 
stool cultures are screened by enzyme 
immunoassay (EIA) for Shiga toxin 
(Premier EHEC, Meridian Bioscience, 
Cincinnati, OH, USA). This rate was 
disproportionately higher than that 
of the remaining 6 health districts, 
which primarily use culture methods 
to screen for E. coli O157:H7. We 
hypothesized that this disproportion 
was due to differences in stool culture 
protocol. To test this premise, we con-
ducted enhanced surveillance for 16 
months in a “low” STEC incidence 
area, Health District 5. A total of 2,065 
stools submitted for culture were 
screened for Shiga toxin by EIA. With 
this approach, reported non-O157 
STEC incidence rose from <1 case/
year/100,000 population to 11 cases/
year/100,000 population. Addition-
ally, 56% of recovered STEC isolates 
were non-O157 serotypes, mirroring 
the proportion of non-O157 detected 
in District 7. Notably, this appears to 
be the endemic rate for District 5 be-
cause no non-O157 STEC outbreaks 
or matching pulsed-ﬁ  eld gel electro-
phoresis patterns were detected dur-
ing the surveillance period. Although 
our study captured only a portion of 
stool cultures in Idaho, our ﬁ  ndings 
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demonstrated increased prevalence of 
non-O157 STEC in the region when 
nonculture methods were used.
Two barriers cited for not routine-
ly screening diarrheal stools for Shiga 
toxin are cost and perception of low 
non-O157 STEC incidence. While 
toxin testing is more expensive than 
culture testing, the potential effects of 
misdiagnosis may outweigh cost con-
cerns. A study estimating the ﬁ  nancial 
repercussions of E. coli O157 infec-
tions in the United States suggested 
that annual cost associated with this 
pathogen is $405 million, with the 
cost per case varying from $26 for 
those who do not seek medical care to 
$6.2 million for a patient with fatal he-
molytic uremic syndrome (HUS) (7). 
Non-O157 STEC infections have been 
an important cause of HUS in many 
countries. For example, a 3-year pro-
spective study in Germany and Aus-
tria reported that non-O157 serotypes 
comprised 90 (43%) of 207 STEC iso-
lates from stools of 394 pediatric pa-
tients with HUS (8). Further, a 6-year 
Danish study of 343 registered STEC 
patients found that 76% of STEC and 
48% of HUS cases were attributable to 
non-O157 serotypes (9). In the United 
States, continued reliance on O157 
STEC culturing hinders our ability to 
determine the ﬁ  nancial effects and the 
proportion of HUS cases attributable 
to non-O157 STEC.
Some evidence suggests that the 
testing focus may be changing in the 
United States. We used US Census 
Bureau population statistics to trans-
late reported O157:H7 and non-O157 
STEC cases for each state into inci-
dence data. Despite widespread varia-
tion in STEC testing and incidence 
among states, there has been a signiﬁ  -
cant statistical decline in the propor-
tion of E. coli O157:H7 among total 
STEC cases every year since 2001 
(Figure; p<0.001) (10). Consistent 
with this trend, the incidence of non-
O157 STEC in the United States has 
increased (10). This may indicate that 
more laboratories are adopting Shiga 
toxin testing protocols, as we are ad-
vocating in Idaho. Our ﬁ  ndings sug-
gest that perceptions of low non-O157 
STEC incidence in Idaho are probably 
artifactual and due to overemphasis on 
culture methods for O157 STEC. Our 
ongoing EIA-based surveillance high-
lights the need for continued investiga-
tion of the epidemiology of non-O157 
STEC disease. We conclude that O157 
STEC culturing has limited usefulness 
in areas like the Idaho health districts 
investigated, where non-O157 sero-
types accounted for 55% of STEC ill-
nesses. The true involvement of non-
O157 in STEC disease will remain 
obscured as long as screening methods 
focus on traditional culture methods.
Acknowledgments
We thank Richard Gelok and staff 
at Eastern Idaho Regional Medical Cen-
ter in Idaho Falls and Janie Palmer and 
staff at St. Luke’s Magic Valley Regional 
Medical Center in Twin Falls for their 
participation. 
Partial support came from the Centers 
for Disease Control and Prevention, Epi-
demiology and Laboratory Capacity grant 
PA-01022.
 Vivian Marie Lockary,* 
Richard Frederick Hudson,* 
and Christopher Lawrence Ball*
*Idaho Bureau of Laboratories, Boise, 
Idaho, USA
References
  1.   Park CH, Kim HJ, Hixon DL. Importance 
of testing stool specimens for Shiga tox-
ins [letter]. J Clin Microbiol. 2002;40:
3542–3.
  2.   Fey PD, Wickert RS, Rupp ME, Safranek 
TJ, Hinrichs SH. Prevalence of non-O157:
H7 Shiga toxin–producing Escherichia 
coli in diarrheal stool samples from Ne-
braska. Emerg Infect Dis. 2000;6:530–3.
  3.   Centers for Disease Control and Preven-
tion. Laboratory-conﬁ  rmed  non-O157 
Shiga toxin–producing Escherichia coli. 
Connecticut, 2000–2005. MMWR Morb 
Mortal Wkly Rep. 2007;56:29–31.
  4.   Jelacic JK, Damrow T, Chen GS, Jelacic 
S, Bielaszewska M, Ciol M, et al. Shiga 
toxin-producing Escherichia coli in Mon-
tana: bacterial genotypes and clinical pro-
ﬁ  les. J Infect Dis. 2003;188:719–29.
  5.   Manning SD, Madera RT, Schneider W, 
Dietrich SE, Khalife W, Brown W, et al. 
Surveillance for Shiga toxin–producing 
Escherichia coli, Michigan, 2001–2005. 
Emerg Infect Dis. 2007;13:318–21.
  6.   Kaper JB, O’Brien AD, eds. Escherichia 
coli O157:H7 and other Shiga toxin–pro-
ducing E. coli Strains. Washington: ASM 
Press; 1998. p. 26, 55.
  7.   Frenzen PD, Drake A, Angulo FJ; Emerg-
ing Infections Program FoodNet Work-
ing Group. Economic cost of illness due 
to  Escherichia coli O157 infections in 
the United States. J Food Prot. 2005;68:
2623–30.
Figure. Shiga toxin–producing Escherichia coli (STEC) incidence trends, United States, 
2002–2005. LETTERS
1264  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 8, August 2007
  8.   Gerber A,  Karch  H, Allerberger  F, Ver-
weyen HM, Zimmerhackl LB. Clinical 
course and the role of Shiga toxin–pro-
ducing  Escherichia coli infection in the 
hemolytic-uremic syndrome in pediatric 
patients, 1997–2000, in Germany and 
Austria: a prospective study. J Infect Dis. 
2002;186:493–500.
  9.   Ethelberg S, Olsen KE, Scheutz F, Jen-
sen C, Schiellerup P, Engberg J, et al. 
Virulence factors for hemolytic uremic 
syndrome, Denmark. Emerg Infect Dis. 
2004;5:842–7.
10.   Centers for Disease Control and Preven-
tion. Summary of notiﬁ  able  diseases, 
United States. [cited 2007 Jan 11]. Avail-
able from http://www.cdc.gov/mmwr/
summary.html
Address for correspondence: Vivian Marie 
Lockary, Idaho Bureau of Laboratories, 2220 
Old Penitentiary Rd, Boise, ID  83712, USA; 
email: lockaryv@dhw.idaho.gov
 
Imported 
Chikungunya 
Infection, Italy
To the Editor: Chikungunya vi-
rus (CHIKV) infection is a self-lim-
iting illness characterized by fever, 
headache, weakness, rash, and arthral-
gia. Some patients have prolonged 
weakness or arthralgia lasting several 
months. In 2006, several Indian Ocean 
states and India had an outbreak of 
CHIKV infection (1,2). During the 
epidemic’s peak, some European and 
American travelers returning from 
these areas were infected (3–6).
Because the foci of Aedes al-
bopictus, 1 of the 2 main vectors of 
CHIKV, are now in Italy and many 
travelers visit CHIKV-epidemic ar-
eas, surveillance for imported cases 
is mandatory in Italy (7). From July 
to September 2006, a total of 17 con-
ﬁ  rmed cases of CHIKV infection were 
observed in travelers at 5 Gruppo di 
Interesse e Studio delle Patologie di 
Importazione (GISPI) centers (Italian 
network of Institutes of Infectious and 
Tropical Diseases). Serologic diagno-
sis was performed with a hemagglu-
tination-inhibition test and conﬁ  rmed 
by a plaque-reduction neutralization 
test (8). Demographic and epidemio-
logic characteristics of these patients 
are reported in the Table.
Cases were distributed through-
out the year with a peak from March 
to May 2006 (n = 10). Nine patients 
(53%) were men. Median age was 
43 years (range 31–66 years). Sev-
eral reasons for travel were reported: 
tourism (64.6%), visits to relatives or 
friends (11.8%), business (11.8%), and 
missionary work (5.9%). One patient 
was a resident in the disease-epidemic 
area. The median exposure time in the 
CHIKV-endemic area for the 15 trav-
elers was 15 days (range 9–93 days) 
(missionary and resident patients were 
excluded). The median delay before 
being seen at a clinic after return was 
2 days (range 0–73 days). Only 7 pa-
tients (41.2%) were hospitalized. The 
remainder were outpatients.
All patients had fever; arthralgia 
(88.2%, n = 15), weakness (70.6%, n 
= 12), headache (11.8%, n = 2), diar-
rhea (11.8%, n = 2), and gum bleeding 
and epistaxis (5.9%, n = 1) were other 
reported symptoms. The median dura-
tion of fever was 5 days (range 2–12 
days). Only 7 of 16 patients (43.8%) 
were still febrile when ﬁ  rst  seen. 
Physical examination showed diffuse 
macular erythematous rash in 13 pa-
tients (76.5%), a similar rate to that 
reported among French travelers (4). 
Hepatomegaly was found in 2 patients 
(11.8%), splenomegaly in 2 (11.8%), 
and peripheral lymphadenopathy in 2 
(11.8%).
Twelve acute-phase patients were 
admitted to the hospital for blood 
testing within 3 days of the initial ex-
amination. In contrast with results of 
other studies, leukopenia and throm-
bocytopenia were uncommon in our 
study. Leukopenia (leukocyte count 
<4,000/μL) was present in 4 patients 
(33.3%) and thrombocytopenia (plate-
let count <150,000/μL) in 1 patient 
(8.3%). This ﬁ  nding may help distin-
guish CHIKV infection from dengue 
fever (4). Anemia (hemoglobin level 
<12 g/dL) was found in only 1 patient 
(8.3%). Alanine aminotransferase 
(ALT) and aspartate aminotransferase 
(AST) determination were available 
for 12 patients. ALT and AST levels 
were elevated (>40 IU/L) in 5 (41.7%) 
and 2 (16.7%) patients, respectively. 
Seven (46.7%) of 15 patients fully 
recovered within 1 month; 8 patients 
(53.3%) reported persistent arthralgia.
Because the GISPI network pro-
vides regional coverage only, the 
number of imported CHIKV cases in 
all of Italy in 2006 was likely higher. 
Moreover, most patients probably did 
not seek medical care, and when they 
did, physicians may have failed to 
recognize the disease because of lack 
of familiarity with it or limited diag-
nostic facilities. Differential diagno-
sis with other arthropodborne viruses 
of the Alphavirus genus (Ross River, 
Barmah Forest, o’nyong nyong, Sind-
bis, and Mayaro viruses) is difﬁ  cult, 
but these are comparatively rare. In 
contrast, dengue and CHIKV epidem-
ics may overlap, and potential patients 
should be screened for both.
The potential risk for introduction 
and establishment of CHIKV reser-
voirs in areas with mosquito vectors 
was discussed in March 2006 by a mul-
tidisciplinary European expert panel 
(9). In Italy, A. albopictus was ﬁ  rst 
recorded in 1990; it has since quickly 
spread across the country. Scattered 
foci are now reported in almost all re-
gions, mainly along the coastal plains, 
from the sea to the inlands, up to an 
altitude of ≈500–600 m (7).
The ability of A. albopictus to 
colonize new areas and its adaptability 
to the mild Italian climate allow vec-
tor populations to be active throughout 
the year (10). The patient is thought to 
be viremic for only 6–7 days (shortly 
before and during the febrile period) 
(6). We were unable to directly assess 